The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

24 articles for P Filippakopoulos


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis.EBI
University of Athens
Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit.EBI
Pfizer
Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening.EBI
The Institute of Cancer Research
Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.EBI
University of Oxford
Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases.EBI
University of Athens
Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.EBI
Pfizer
Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.EBI
Cnrs
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.EBI
University of Oxford
7,8-dichloro-1-oxo-ß-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.EBI
Ludwig-Maximilians University of Munich
3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.EBI
University of Oxford
Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.EBI
Universite£? De Rennes 1
Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.EBI
Clermont Universit£
Discovery of Novel BRD4 Ligand Scaffolds by Automated Navigation of the Fragment Chemical Space.EBI
Universitat De Barcelona
Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.EBI
University of Oxford
Selective inhibition of BET bromodomains.EBI
University of Oxford
Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.EBI
University of Oxford
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.EBI
University of Oxford
Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance.EBI
University of Oxford
The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains.EBI
University of Oxford
[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.EBI
University of Oxford
BET bromodomain ligands: Probing the WPF shelf to improve BRD4 bromodomain affinity and metabolic stability.EBI
University of Oxford
2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereofBDB
Shanghai Haiyan Pharmaceutical Technology
Inhibitors of the fibroblast growth factor receptorBDB
Blueprint Medicines
Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity.BDB
F. Hoffmann-La Roche